DK3009133T3 - Farmaceutisk sammensætning til anvendelse ved behandling eller forebyggelse af vitamin- og mineralmangler hos en patient, som har været udsat for en gastrisk bypass-operation - Google Patents

Farmaceutisk sammensætning til anvendelse ved behandling eller forebyggelse af vitamin- og mineralmangler hos en patient, som har været udsat for en gastrisk bypass-operation Download PDF

Info

Publication number
DK3009133T3
DK3009133T3 DK15171583.6T DK15171583T DK3009133T3 DK 3009133 T3 DK3009133 T3 DK 3009133T3 DK 15171583 T DK15171583 T DK 15171583T DK 3009133 T3 DK3009133 T3 DK 3009133T3
Authority
DK
Denmark
Prior art keywords
vitamin
patients
less
pharmaceutical composition
iron
Prior art date
Application number
DK15171583.6T
Other languages
English (en)
Inventor
Simon Hamer
Original Assignee
Fit For Me B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52472487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3009133(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fit For Me B V filed Critical Fit For Me B V
Application granted granted Critical
Publication of DK3009133T3 publication Critical patent/DK3009133T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pediatric Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (15)

1. Farmaceutisk sammensætning til anvendelse ved behandling eller forebyggelse af vitamin- og mineralmangler hos patienter, som har været udsat for en gastrisk bypass-operation, omfattende: - vitamin B12 eller en kilde deraf; - vitamin B6 eller en kilde deraf; - jern eller en kilde deraf; - en farmaceutisk acceptabel bærer; og hvor patienterne med behov herfor indgives ved hjælp af sammensætningen pr. dag 250 til 500 pg vitamin B12, 0,5 til 1,5 mg vitamin B6 og 50 til 150 mg jern.
2. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor en doseringsenhed af sammensætningen omfatter: - 250 til 500 pg vitamin B12; - 0,5 til 1,5 mg vitamin B6; - 50 til 150 mg jern; - mindre end 0,1 mg calcium; - mindre end 0,1 pg vitamin K; og et farmaceutisk acceptabelt hjælpestof.
3. Farmaceutisk sammensætning ifølge krav 1 eller 2, til anvendelse hos patienter, som har været udsat for en Roux-en-Y Gastric Bypass (RYGB).
4. Farmaceutisk sammensætning til anvendelse ifølge et af de foregående krav, hvor sammensætningen indgives i det mindste en gang dagligt til patienter med behov herfor.
5. Farmaceutisk sammensætning til anvendelse ifølge et af de foregående krav, hvor en doseringsenhed af sammensætningen yderligere omfatter: - 15 til 30 mg zink; - 400 til 800 pg folsyre; - mindre end 1 mg, fortrinsvis mindre end 0,1 mg magnesium.
6. Farmaceutisk sammensætning til anvendelse ifølge et af de foregående krav, hvor sammensætningen er formuleret som en fast kombinationsdosis, fortrinsvis som en oral fast kombinationsdosis.
7. Farmaceutisk sammensætning til anvendelse ifølge det foregående krav, hvor den orale faste kombinationsdosis er en fast doseringsform, såsom en kapsel, tablet eller et pulver.
8. Terapeutisk kombination til anvendelse ved behandling eller forebyggelse af vitamin- og mineralmangler hos patienter, som har været udsat for en gastrisk bypass-operation, hvor sammensætningen omfatter: (a) en første doseringsenhed omfattende: - 250 til 500 pg vitamin B12; - 0,5 til 1,5 mg vitamin B6; - 50 til 150 mg jern; - mindre end 0,1 mg calcium; - mindre end 0,1 pg vitamin K; og (b) en anden doseringsenhed omfattende - 450 til 3000 mg calcium; - 5 til 15 pg vitamin D. - 50 til 250 pg vitamin K.
9. Terapeutisk kombination ifølge krav 8, til anvendelse hos patienter, som har været udsat for en Roux-en-Y Gastric Bypass (RYGB).
10. Terapeutisk kombination til anvendelse ifølge krav 8 eller 9, hvor kombinationen indgives i det mindste en gang dagligt til patienter med behov herfor.
11. Terapeutisk kombination til anvendelse ifølge et af kravene 8-10, hvor den anden doseringsenhed indgives til en patient med behov herfor mindst en time, fortrinsvis mindst to timer og mere foretrukket mindst tre timer efter eller inden indgivelse af den første doseringsenhed til patienten.
12. Terapeutisk kombination til anvendelse ifølge et af kravene 8-11, hvor den første doseringsenhed yderligere omfatter: - 15 til 30 mg zink; - 400 til 800 pg folsyre; - mindre end 1 mg, fortrinsvis mindre end 0,1 mg magnesium.
13. Terapeutisk kombination ifølge et af kravene 8-12, hvor den første doseringsenhed og/eller den anden doseringsenhed er en fast kombinationsdosis, fortrinsvis en oral fast kombinationsdosis, mest foretrukket en tablet, kapsel eller et pulver.
14.
Farmaceutisk sammensætning omfattende: - 250 til 500 pg vitamin B12; - 0,5 til 1,5 mg vitamin B6; - 50 til 150 mg jern; - mindre end 0,1 mg calcium; - mindre end 0,1 pg vitamin K; - 15 til 30 mg zink; - 400 til 800 pg folsyre; - mindre end 1 mg, fortrinsvis mindre end 0,1 mg magnesium; og et farmaceutisk acceptabelt hjælpestof.
DK15171583.6T 2014-10-17 2015-06-11 Farmaceutisk sammensætning til anvendelse ved behandling eller forebyggelse af vitamin- og mineralmangler hos en patient, som har været udsat for en gastrisk bypass-operation DK3009133T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2013645A NL2013645C2 (en) 2014-10-17 2014-10-17 Pharmaceutical composition for use in the treatment or prevention of vitamin and mineral deficiencies in patients which have been subjected to gastric bypass-surgery.

Publications (1)

Publication Number Publication Date
DK3009133T3 true DK3009133T3 (da) 2016-12-19

Family

ID=52472487

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15171583.6T DK3009133T3 (da) 2014-10-17 2015-06-11 Farmaceutisk sammensætning til anvendelse ved behandling eller forebyggelse af vitamin- og mineralmangler hos en patient, som har været udsat for en gastrisk bypass-operation

Country Status (23)

Country Link
US (1) US20170290364A1 (da)
EP (1) EP3009133B1 (da)
CN (1) CN107106601A (da)
AR (1) AR102308A1 (da)
AU (1) AU2015331035A1 (da)
BR (1) BR112017007364B1 (da)
CA (1) CA2964197A1 (da)
CL (1) CL2017000884A1 (da)
CY (1) CY1118532T1 (da)
DK (1) DK3009133T3 (da)
ES (1) ES2606200T3 (da)
HR (1) HRP20161796T1 (da)
HU (1) HUE030367T2 (da)
IL (1) IL251687B (da)
LT (1) LT3009133T (da)
MX (1) MX370436B (da)
NL (1) NL2013645C2 (da)
PL (1) PL3009133T3 (da)
PT (1) PT3009133T (da)
RS (1) RS55508B1 (da)
SI (1) SI3009133T1 (da)
SM (1) SMT201600460B (da)
WO (1) WO2016060559A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2019348B3 (en) * 2017-07-26 2019-09-05 Ams Advanced Medical Supplements B V Pharmaceutical composition for use in the treatment or prevention of vitamin deficiency and mineral deficiency in patients who have been subjected to gastric sleeve surgery
CA3027648C (en) * 2017-12-22 2023-11-21 Mantra Pharma Nutritional formulations and kits for bariatric individuals
WO2020242306A1 (en) * 2019-05-28 2020-12-03 Espera Supplements B.V. Pharmaceutical composition for treatment of vitamin deficiencies and mineral deficiencies after pancreaticoduodenectomy
CN111513322A (zh) * 2020-05-29 2020-08-11 成都尚医信息科技有限公司 一种用于减重术后病人的流质食品及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032741A1 (en) * 2003-08-06 2005-02-10 Balaji Venkataraman Vitamin Compositions
CN101401644A (zh) * 2008-10-08 2009-04-08 北京冠五洲生物科学研究院 用于预防出生缺陷和改善记忆的药物组合物
US20100227001A1 (en) * 2009-03-05 2010-09-09 Silvia Demeter Method of delivering nutrients

Also Published As

Publication number Publication date
MX2017004723A (es) 2017-11-30
IL251687A0 (en) 2017-06-29
IL251687B (en) 2020-03-31
CY1118532T1 (el) 2017-07-12
AU2015331035A1 (en) 2017-04-27
PT3009133T (pt) 2016-12-27
PL3009133T3 (pl) 2017-07-31
SMT201600460B (it) 2017-03-08
EP3009133B1 (en) 2016-10-05
WO2016060559A1 (en) 2016-04-21
CN107106601A (zh) 2017-08-29
RS55508B1 (sr) 2017-05-31
BR112017007364A2 (pt) 2017-12-19
NL2013645C2 (en) 2015-06-11
US20170290364A1 (en) 2017-10-12
CL2017000884A1 (es) 2018-01-05
AR102308A1 (es) 2017-02-15
BR112017007364B1 (pt) 2021-12-14
LT3009133T (lt) 2017-03-10
HUE030367T2 (en) 2017-05-29
CA2964197A1 (en) 2016-04-21
MX370436B (es) 2019-12-13
ES2606200T3 (es) 2017-03-23
SI3009133T1 (sl) 2017-04-26
HRP20161796T1 (hr) 2017-03-24
EP3009133A1 (en) 2016-04-20

Similar Documents

Publication Publication Date Title
TWI457079B (zh) 複維生素及礦物質補充劑
US7205007B2 (en) Peri-operative and peri-procedure nutritional supplementation
DK3009133T3 (da) Farmaceutisk sammensætning til anvendelse ved behandling eller forebyggelse af vitamin- og mineralmangler hos en patient, som har været udsat for en gastrisk bypass-operation
UA81973C2 (uk) Композиція, придатна для прискорення зрощення кісток, та її застосування
CN105658093A (zh) 用于预防和治疗第2型糖尿病的营养品组合
Melamed et al. CKD-mineral bone disorder in stage 4 and 5 CKD: what we know today?
EP3658159B1 (en) Pharmaceutical composition for use in the treatment or prevention of vitamin deficiency and mineral deficiency in patients who have been subjected to gastric sleeve surgery
EP2845598B1 (en) Preparation for use in the prophylaxis and treatment of atypical osteoporosis
CN110087664B (zh) 用于治疗骨科疾病的组合物和方法
Singh et al. One Anastomosis Gastric Bypass Surgery: Consequences Over Ascorbic Acid, Cobalamin, 2 Calciferol, and Calcium. 3 Bariatric Surgery Series: Paper I. 4 Short Title: Gastric Bypass Surgery: Consequences Over Vitamins and Ca2+ 5
US20180193312A1 (en) Nutraceutical composition and dosing regimen
Abdalla et al. Intensification of Weight Loss with the Ketogenic Diet during the Management of a Super Obese: Case Study
Sobhani et al. Changes of Serum 25OH-vitaminD Level in Patients with Morbid Obesity after Sleeve Gastrectomy in Iranian Population
Díaz Curiel Action of vitamin K on bone health.
McHenry Martin Vitamins for the elderly: from A to zinc
US20080070845A1 (en) Method and formulations to concurrently reduce fracture risk and insure appropriate fat-soluble vitamin supplementation when using Orlistat, an oral lipase inhibitor
US20240041816A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
Goldenberg Mechanisms of metabolic bone disease in bariatric surgery patients
Patankar et al. Effect of balanced low calorie meal replacement formula diet in the management of overweight/obesity and metabolic profile-a retrospective clinical experience report
Brady et al. OsteoForce™
Srikanth et al. Preoperative diagnosis and treatment of abnormal calcium metabolism in morbidly obese patients: Implications for choosing appropriate type of bariatric surgery
TW201733572A (zh) 用於預防及治療第２型糖尿病之營養品組合